Precision BioSciences, Inc. (NASDAQ: DTIL) is a Healthcare company (Biotechnology) with a market capitalization of $197M. The Maz Rating grades it against the other companies in its sector.
Precision BioSciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.05, Precision BioSciences, Inc. trades at 4.4x sales and 3.7x book value. Over the last twelve months it generated about $45M of revenue and a net loss of $35M. It runs a gross margin of 98.7%, an operating margin of -80.3% and a net margin of -85.6%. It shows return on equity of -58.1%, return on invested capital of -31.8% and a free cash flow yield of -26.2%. On the balance sheet: a debt-to-equity ratio of 0.54 and a current ratio of 10.47. Over the past 52 weeks the share price ranged from $3.53 to $11.29, with a beta of 1.35.
Precision BioSciences, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 9 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.